Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy
Chuan Qin, Minghao Dong, Luo‐Qi Zhou, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 25

Showing 25 citing articles:

Advancements and challenges in CAR T cell therapy in autoimmune diseases
Georg Schett, Fabian Müller, Jule Taubmann, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 9, pp. 531-544
Closed Access | Times Cited: 34
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
Aiden Haghikia, Georg Schett, Dimitrios Mougiakakos
The Lancet Neurology (2024) Vol. 23, Iss. 6, pp. 615-624
Open Access | Times Cited: 19
B-cell depletion in autoimmune diseases
Georg Schett, György Nagy, Gerhard Krönke, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225727
Closed Access | Times Cited: 14
Immune-mediated necrotizing myopathy: A comprehensive review of the pathogenesis, clinical features, and treatments
Changpei Li, Hongjiang Liu, Leiyi Yang, et al.
Journal of Autoimmunity (2024) Vol. 148, pp. 103286-103286
Closed Access | Times Cited: 5
Recent Updates on the Pathogenesis of Inflammatory Myopathies
Jon Musai, Andrew L. Mammen, Iago Pinal‐Fernandez
Current Rheumatology Reports (2024) Vol. 26, Iss. 12, pp. 421-430
Open Access | Times Cited: 5
Application of novel CAR technologies to improve treatment of autoimmune disease
Abigail Cheever, Chloe C. Kang, Kim L. O’Neill, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Highlighting individual patient data related to chimeric antigen receptor T-cell therapy in refractory autoimmune rheumatic diseases
Mads Lamm Larsen, Anne Voss, Christoffer Tandrup Nielsen, et al.
Scandinavian Journal of Rheumatology (2025), pp. 1-6
Open Access
Current advancements in cellular immunotherapy for autoimmune disease
Corbett T. Berry, C. Pritchett Frazee, Patrick J. Herman, et al.
Seminars in Immunopathology (2025) Vol. 47, Iss. 1
Open Access
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
La déplétion totale des lymphocytes B : un espoir de guérison des maladies auto-immunes ?
Xavier Mariette
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Defining immune reset: achieving sustained remission in autoimmune diseases
Tobias Junt, Thomas Calzascia, Elisabetta Traggiai, et al.
Nature reviews. Immunology (2025)
Closed Access
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
L. M. Carter, Michael R. Ehrenstein, Edward M Vital
The Lancet Rheumatology (2025)
Closed Access
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Marc Scherlinger, Gaétane Nocturne, Marko Radic, et al.
The Lancet Rheumatology (2025)
Closed Access
Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy
Zhihou Liang, Hui Xie, Dongze Wu
Frontiers in Immunology (2025) Vol. 16
Open Access
Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy
Tao Liu, Bo Chen, Geng Yin, et al.
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Open Access
Case study of CD19-directed chimeric antigen receptor T-cell therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis™ phase I/II trial
Jenell Volkov, Daniel Núñez, Tahseen Mozaffar, et al.
Molecular Therapy (2024)
Open Access | Times Cited: 4
Disappearance of Antiphospholipid Antibodies after anti-CD19 CAR T-Cell Therapy of B-Cell Lymphoma in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Eleonora Friedberg, Philipp Wohlfarth, Ana Iris Schiefer, et al.
Journal of Thrombosis and Haemostasis (2024)
Closed Access | Times Cited: 3
New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy
Weiteng Wang, Hao Jia, Xiumeng Hua, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 5, pp. 883-907
Closed Access | Times Cited: 1
The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus
Thomas Dörner, Peter E. Lipsky
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 12, pp. 770-782
Closed Access | Times Cited: 1
The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment
Qianyu Guo, Jie Li, Juanjuan Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications
Liuting Zeng, Yan Li, Xiang Wang, et al.
Journal of Autoimmunity (2024) Vol. 150, pp. 103350-103350
Closed Access | Times Cited: 1
Distinct pathogenic influence of anti-HMGCR+ and anti-SRP+ immune-mediated necrotizing myopathy autoantibodies on engineered muscle function
Heta Lad, Ernest Myguel Esteban, Yekaterina Tiper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies
Hanna Kim
Pediatric Drugs (2024)
Open Access
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Jie Liu, Zhao Yan, Zhao Hai
Frontiers in Immunology (2024) Vol. 15
Open Access
From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
Yannick Bulliard, Robert A. Freeborn, Molly Javier Uyeda, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top